Your browser doesn't support javascript.
loading
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
Ferrero, S; Gentile, Massimo; Laurenti, Luca; Mauro, Francesca Romana; Martelli, Maurizio; Sportoletti, Paolo; Visco, Carlo; Zinzani, Pier Luigi; Tedeschi, Alessandra; Varettoni, M.
Afiliação
  • Ferrero S; Department of Molecular Biotechnologies and Health Sciences, Division of Haematology, University of Torino, Torino, Italy.
  • Gentile M; AOU "Città della Salute e della Scienza di Torino", Torino, Italy.
  • Laurenti L; UOC Ematologia AO Cosenza, Cosenza, Italy.
  • Mauro FR; Hematology, Università Cattolica del Sacro Cuore, Policlinico A, Rome, Italy.
  • Martelli M; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Sportoletti P; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Visco C; Department of Medicine, Institute of Hematology-Centro di Ricerche Emato-Oncologiche (CREO), University of Perugia, Perugia, Italy.
  • Zinzani PL; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Tedeschi A; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italy.
  • Varettoni M; Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Hematol Oncol ; 40(3): 332-340, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35212014
ABSTRACT
The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar clinical situations. A panel of experts from Italy was convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases in general, and in patients with WM in particular. This position paper represents the panel's collective analysis, evaluation, and opinions and is made up of a series of questions frequently asked by practicing clinicians and answers based on currently available evidence.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Macroglobulinemia de Waldenstrom Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Hematol Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Macroglobulinemia de Waldenstrom Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Hematol Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália